Company news
HLS Therapeutics, Inc. news in 2020
HLS Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
HLS Therapeutics Announces Update on Health Canada Filings for MyCare and Trinomia
December 16, 2020
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl)
December 14, 2020
HLS Therapeutics Announces Health Canada Approval of PERSERIS® for the Treatment of Schizophrenia
November 17, 2020
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Coronary Artery Bypass Grafting Procedures
November 16, 2020
HLS Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
November 12, 2020
HLS Therapeutics Announces Q3 2020 Financial Results and Normal Course Issuer Bid
November 5, 2020
HLS Therapeutics to Host Q3 2020 Financial Results Conference Call
October 27, 2020
HLS Therapeutics Highlights Latest Icosapent Ethyl Research Presented at the Canadian Cardiovascular Congress
October 22, 2020
HLS Therapeutics Acquires Portfolio of Four Royalty Interests
September 30, 2020
HLS Therapeutics Comments on U.S. Court of Appeals Decision in Amarin Patent Litigation
September 3, 2020
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ESC Congress 2020
August 31, 2020
HLS Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
August 7, 2020
HLS Therapeutics Announces Q2 2020 Financial Results
August 6, 2020
HLS Therapeutics to Host Q2 2020 Financial Results Conference Call
July 30, 2020
HLS Therapeutics welcomes both CADTH's recommendation to reimburse Vascepa® (icosapent ethyl) for patients with established cardiovascular disease and PMPRB's notification on its introductory price
July 20, 2020
HLS Therapeutics to Present at the Raymond James Human Health Innovation Conference
June 17, 2020
HLS Therapeutics Confirms Annual Shareholders' Meeting
June 10, 2020
HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference
June 1, 2020
HLS Therapeutics to Become Distributor of the Saladax MyCare(TM) Psychiatry Line including the Insite Point-of-Care Device and Antipsychotic Reagents
June 1, 2020
HLS Therapeutics Supports Trial to Investigate the Effects of Vascepa® (Icosapent Ethyl) against COVID-19
May 21, 2020
HLS Therapeutics Announces Q1 2020 Financial Results
May 7, 2020
HLS Therapeutics to Host Q1 2020 Financial Results Conference Call
April 30, 2020
HLS Therapeutics Comments on U.S. District Court Decision on Amarin Patents
March 31, 2020
HLS Therapeutics Announces Fourth Quarter and Fiscal 2019 Financial Results
March 19, 2020
HLS Therapeutics to Host Q4 and Fiscal 2019 Financial Results Conference Call
February 27, 2020
HLS Therapeutics Provides Investor Update on the Canadian Launch of Vascepa® (Icosapent Ethyl)
January 28, 2020
HLS Therapeutics Files New Drug Submission for PERSERIS® in Canada
January 23, 2020
HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®
January 6, 2020
Decks in 2020
- Investor Presentation (November 2020)
Investor deck · 22 slides · Nov 5, 2020
- Investor Presentation (September 2020)
Investor deck · 20 slides · Sep 24, 2020
- Q1 2020 Earnings Presentation
Earnings · 22 slides · May 7, 2020